Sub-category: Tissue Engineering & Cell Therapy
Medical field: Peripheral Vascular
BioGenCell is a clinical stage, Biotechnology company in the field of regenerative medicine, located in the Laniado Hospital, Sanz Medical Netanya, Israel. BioGenCell was established since One out of Four people in the world dies from vascular diseases. Millions of them suffer and die every year as modern medicine has not yet found effective and long lasting treatment for these diseases.
The company is developing a biotechnology platform, enabling effective, affordable and accessible personalized cell therapy for the treatment of vascular diseases. Our leading product BCG101, is designed to treat Critical Limb Ischemia, a chronic condition typical of diabetic and smoking populations, leading to amputation and death.
We have completed our first-in-human trial with very promising results on CLI patients who have exhausted all other treatment options (clinicaltrials.gov Identifier: NCT02805023). The goal beyond elimination of leg amputations is to extend lifespan and improve functionality and quality of life in these patients. The treatment was found safe and met the primary efficacy endpoint of 6month amputation free survival. Now, two years after a single treatment, patients continue to experience wound healing and walking ability improvement, reduction of pain and elimination of the use of narcotic medication resulting in a major improvement in their quality of life.
The Laniado Hospital has obtained approval in an exceptionally fast track by the Israel Ministry of Health for compassionate use of our BGC101. The treatment is essentially a life-saving procedure for the patients targeted in the compassionate use setting.
|Yael Porat, CEO|
|47 Herzel St., Hod-Hasharon|
To update your company data, click here.